• +353-1-415-1241(GMT OFFICE HOURS)
  • 1-800-526-8630(US/CAN TOLL FREE)
  • 1-917-300-0470(EST OFFICE HOURS)
Colombia Pharmaceuticals and Healthcare Report Q1 2013 - Product Image

Colombia Pharmaceuticals and Healthcare Report Q1 2013

  • Published: February 2013
  • Region: Colombia
  • 114 pages
  • Business Monitor International

BMI View

Improvements in Colombia's pharmaceutical regulation system will expand local patients'
access to medicines. However, it will also put pricing pressures on drugmakers, and promote the use of generic versions, which will undermine the growth of patented drug market. Nevertheless, BMI expects more foreign pharmaceutical companies to invest in Colombia, capitalising on the country's strong longterm growth prospects.

Headline Expenditure Projections

- Pharmaceuticals: COP7,076bn (US$3.83bn) in 2011 to COP7,612bn (US$4.23bn) in 2012;
+7.6% in local currency terms and +10.4% in US dollar terms. Forecast broadly in line with Q412.

- Healthcare: COP29,953bn (US$16.21bn) in 2011 to COP31,557bn (US$17.53bn) in 2012;
+5.4% growth in local currency terms and +8.2% in US dollar terms. Forecast broadly in line with Q412.

- Medical devices: COP1,901bn (US$1.03bn) in 2011 to COP2,127bn (US$1.18bn) in 2012;
+11.9% growth in local currency terms and +14.9% in US dollar terms. Forecast broadly in line with Q412.

Executive Summary 7

SWOT Analysis 9

Colombia Pharmaceutical And Healthcare Industry SWOT 9

Colombia Political SWOT 10

Colombia Economic SWOT 10

Colombia Business Environment SWOT 11

Pharmaceutical Risk/Reward Ratings 12
Table: Americas Pharmaceutical Risk/Reward Ratings, Q113 12

Rewards 13

Risks 13

Colombia - Market Overview 15

Regulatory Regime 16

Other Regulatory Issues 17

Recent Regulatory Developments 18

Pharmaceutical Advertising 18

Intellectual Property Regime 19

Intellectual Property Shortcomings 21

Counterfeit Pharmaceuticals 22

Health-Related Litigation 24

Free Trade Agreement With The US 24
Table: Colombia-US FTA Mechanisms Relevant To Intellectual Property 25

Pricing Regime 25
Table: New Drug Pricing Classification by Type, 2005 26

Recent Pricing Regime Developments 27

Reimbursement Regime 28

National Drug Policy 30

Industry Developments 31

Epidemiology 31

HIV/AIDS 32

Healthcare Sector 33

Healthcare Insurance 34

Private Health Insurance 37

Healthcare Insurance Funding 37

Emergency Healthcare Reform 38

Medical Tourism 39

Research and Development (R&D) 39
Table: Pharmaceutical Research and Science Centre (CECIF) Members, 2012 40

Clinical Trials 41

Medical Devices 42

Industry Forecast Scenario 44

Pharmaceutical Market Forecast 44
Table: Pharmaceutical Sales, 2008-2016 44

Healthcare Market Forecast 46
Table: Overall Healthcare Expenditure, 2008-2016 48
Table: Government Healthcare Expenditure, 2008-2016 48
Table: Private Healthcare Expenditure, 2008-2016 49

Key Growth Factors - Macroeconomic 50

Prescription Drug Market Forecast 52
Table: Prescription Drug Sales, 2008-2016 53

Patented Drug Market Forecast 54
Table: Patented Drug Sales, 2008-2016 55

Generic Drug Market Forecast 56
Table: Generic Drug Sales, 2008-2016 57

OTC Medicine Market Forecast 58
Table: OTC Medicine Sales, 2008-2016 59

Pharmaceutical Trade Forecast 61
Table: Pharmaceutical Trade, 2009-2016 63

Medical Device Market Forecast 64
Table: Medical Device Sales, 2008-2016 64

Other Healthcare Data Forecasts 66

Key Risks To BMI's Forecast Scenario 66

Competitive Landscape 67

Pharmaceutical Industry 67
Table: Pharmaceutical Producers, 2000-2009 68
Table: Pharmaceutical Production, 2000-2009 68
Table: Pharmaceutical Personnel, 2000-2009 69

Domestic Pharmaceutical Sector 69

Foreign Pharmaceutical Sector 70
Table: Members Of Asociación De Laboratorios Farmacéuticos De Investigación (AFIDRO), 2012 70
Table: Leading Pharmaceutical Companies By Revenues, 2011 (COPmn) 71
Table: Leading Pharmaceutical Importers/Wholesalers By Revenues, 2011 73
Table: INVIMA-Certified Pharmaceutical Manufacturing Establishments, October 15 2010 74

Pharmaceutical Company Developments 80

Pharmaceutical Wholesale 81

Pharmaceutical Retail 82
Table: Leading Pharmaceutical Retailers, 2009-2010 83

Company Profiles 86

Local Companies 86

Tecnoquímicas 86

Lafrancol 89

Laboratorios Genfar SA 92

Laboratorios Bussié 94

Multinational Companies 96

GlaxoSmithKline 96

Pfizer 98

Merck & Co 00

Sanofi 02

Novartis 04

Demographic Outlook 105
Table: Population By Age Group, 1990-2020 ('000) 05
Table: Population By Age Group, 1990-2020 (% of total) 06
Table: Key Population Ratios, 1990-2020 07
Table: Rural And Urban Population, 1990-2020 07

Glossary 108

BMI Methodology 110

How We Generate Our Pharmaceutical Industry Forecasts 10

Pharmaceutical Risk/Reward Ratings Methodology 11

Ratings Overview 11
Table: Pharmaceutical Risk/Reward Indicators 12

Weighting 13
Table: Weighting Of Components 13

Sources 13

Note: Product cover images may vary from those shown

RELATED PRODUCTS

Our Clients

Our clients' logos